Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03539965 | Triple-negative Breast Cancer: a New Perspective on Biomarkers(TNBCbrazil) | completed | — | 239 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | May 31, 2018 | clinicaltrials |
| NCT01091454 | Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 48 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 8, 2018 |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01624441 | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2018 | clinicaltrials |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 112 | Merrimack PharmaceuticalsINDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 4 | Mar 6, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03444025 | Neoadjuvant Goserelin for Triple Negative Breast Cancer(NeoGONT) | unknown | Phase 2 | 180 | Kasr El Aini HospitalOTHER | 0 | Feb 23, 2018 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00998036 | Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | completed | Phase 1 | 9 | Columbia UniversityOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT03348098 | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01307891 | Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer | completed | Phase 2 | 64 | University of Alabama at BirminghamOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01319539 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01104259 | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer | completed | Phase 1 | 50 | University of WashingtonOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 11 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors(I-CREST) | withdrawn | N/A | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01639248 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | completed | Phase 2 | 41 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT02511847 | Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | unknown | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | unknown | Phase 2 | 164 | Russian Academy of Medical SciencesOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | unknown | Phase 2 | 45 | Istituti Ospitalieri di CremonaOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT02616848 | Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | unknown | Phase 1 | 1 | Istituti Ospitalieri di CremonaOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02615457 | Huaier Granule in Treating Women With Triple Negative Breast Cancer | unknown | Phase 4 | 300 | Shandong UniversityOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT02595138 | Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | unknown | Phase 3 | 430 | Chinese Academy of Medical SciencesOTHER | 0 | Nov 3, 2015 | clinicaltrials |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | terminated | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT01071564 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00951054 | A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 61 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01238952 | Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | completed | Phase 1 | 4 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT02012634 | Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer(MACRO) | unknown | — | 340 | Xijing HospitalOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT01292083 | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Feb 6, 2014 | clinicaltrials |
| NCT01695057 | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 28, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01111175 | Triple Negative Breast Cancer Biomarker Study | completed | — | 14 | US Oncology ResearchINDUSTRY | 1 | Jul 23, 2013 | clinicaltrials |
| NCT01276769 | Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 16, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 31, 2018source: clinicaltrials